Search

everythinglearnresearchcommunity

for

Search:↓

Different body areas have unique skin cell communication patterns, explaining why certain skin diseases occur in specific regions.

Alarmin cytokines are key in controlling skin immunity and inflammation.

PX-12 may help treat psoriasis by blocking inflammation and cell death.

IL-25 helps heal diabetic wounds by improving blood vessel and skin cell functions.

Ancient immune and signaling pathways still regulate blood cell development.

IL-4 and IL-13 might play a role in a type of hair loss similar to alopecia areata.

Four specific genes are linked to keloid formation and could be potential treatment targets.

CXCL12 can both help and harm hair growth in alopecia areata.

IL-17 is a key target for treating inflammatory skin diseases, especially psoriasis.

Super-enhancers control CD25 expression in specific cell types, affecting immune function.

Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.

Proinflammatory fibroblasts and vascular endothelial cells are key in keloid development.

New therapies are being developed that target integrin pathways to treat various diseases.

Certain immune cells, when activated by specific signals, can encourage hair growth.

New findings suggest targeting IL-23 could treat psoriasis, skin cells can adapt to new roles, direct conversion of skin cells to blood cells may aid cell therapy, removing certain tumor cells could boost cancer immunotherapy, and melanoma may have many tumorigenic cells, not just cancer stem cells.

IL-15 promotes hair growth and protects hair follicles.

IL-1 signaling is crucial for hair follicle stem cell growth and wound healing.

Targeting Interleukin-13 could help treat alopecia areata linked with atopic dermatitis.

Inhibiting IL-17 and IL-23 improves wound healing in obese, diabetic mice by promoting healing macrophages.

IL-17 is more important than IFN-γ in causing severe hair loss in chronic alopecia areata.

Psoriasis may be chronic because it lacks certain immune system controls that prevent overreaction.

ILC1 cells contribute to hair loss in alopecia areata.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

Blocking certain pathways with kinase inhibitors may help treat cutaneous lupus erythematosus.

IL-27 may help prevent hair loss by creating immune-suppressing cells.

IL-17C is important in inflammatory skin diseases and could be a target for treatment.

TSLP affects atopic dermatitis by increasing sebum and reducing fat through IL-4/IL-13 signaling.

ILC1-like cells can cause alopecia areata by themselves.

Higher levels of certain immune cells and proteins are linked to more severe lupus symptoms.

Alopecia areata involves both innate and adaptive immunity, with specific genes linked to the disease.